The IR of composite anemia outcome was lower in patients receiving SGLT2 inhibitors (8.33 [95% CI, 8.03-8.64] per 100 person-years) than in those receiving GLP-1 RAs (10.20 [95% CI, 9.26-11.21] per 100 person-years), yielding an HR of 0.81 (95% CI, 0.73-0.90) (eFigure 3 in Supplement 1). This evidence concerns the gene GLP1R and anemia (phenotype).